BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Díaz-Rodríguez E, Gandullo-Sánchez L, Ocaña A, Pandiella A. Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs. Cancers (Basel) 2021;14:154. [PMID: 35008318 DOI: 10.3390/cancers14010154] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Gámez-Chiachio M, Sarrió D, Moreno-Bueno G. Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs. Cancers (Basel) 2022;14:4543. [PMID: 36139701 DOI: 10.3390/cancers14184543] [Reference Citation Analysis]
2 Han S, Lim KS, Blackburn BJ, Yun J, Putnam CW, Bull DA, Won Y. The Potential of Topoisomerase Inhibitor-Based Antibody–Drug Conjugates. Pharmaceutics 2022;14:1707. [DOI: 10.3390/pharmaceutics14081707] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Yu J, Fang T, Yun C, Liu X, Cai X. Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers. Front Mol Biosci 2022;9:847835. [DOI: 10.3389/fmolb.2022.847835] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
4 Pérez Piñero C, Rivero EM, Gargiulo L, Rodríguez MS, Bruque CD, Bruzzone A, Lüthy IA. Adrenergic receptors in breast cancer. Progress in Molecular Biology and Translational Science 2022. [DOI: 10.1016/bs.pmbts.2022.06.002] [Reference Citation Analysis]